Searched for: in-biosketch:true
person:yazicy01
Effect of Apremilast on Quality of Life and Physical Function in Patients with Behcet's Syndrome. [Meeting Abstract]
Hatemi, Gulen; Melikoglu, Melike; Tunc, Recep; Korkmaz, Cengiz; Ozturk, Banu Turgut; Mat, Cem; Merkel, Peter A; Calamia, Kenneth; Pineda, Lilia; Liu, Ziqi; Stevens, Randall M; Yazici, Hasan; Yazici, Yusuf
ISI:000344384906089
ISSN: 2326-5205
CID: 1444172
Treatment of Mucocutaneous Manifestations in Behcet's Disease with Anakinra: A Pilot Open-Label Study. [Meeting Abstract]
Grayson, Peter C; Yazici, Yusuf; Novakovich, Elaine; Joyal, Elizabeth; Goldbach-Mansky, Raphaela T; Sibley, Cailin H
ISI:000344384905433
ISSN: 2326-5205
CID: 1444222
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis. [Meeting Abstract]
Yazici, Yusuf; Luo, Chunqiao; Swearingen, Christopher
ISI:000344384905205
ISSN: 2326-5205
CID: 1444152
Is there a direct relationship between serum level of methotrexate and clinical efficacy and tolerability? [Letter]
Fleischmann, Roy; Yazici, Yusuf
PMID: 24894190
ISSN: 0003-4967
CID: 1030962
Headache in Behcet's Syndrome: Review of Literature and NYU Behcet's Syndrome Center Experience
Vishwanath, Vijay; Wong, Ericka; Crystal, Sara C; Robbins, Matthew S; Filopoulos, Maria; Lipton, Richard B; Yazici, Yusuf; Kister, Ilya
Headache, a common and disabling symptom in Behcet's syndrome, may be associated with a variety of neurologic syndromes and ocular inflammation, or may present as an isolated feature. Our objective is to describe the various neurologic and ocular syndromes of Behcet's syndrome of which headache is a symptom, and to review the features of isolated headaches in Behcet's. We also report results of a study of headache in Behcet's syndrome patients who are followed at NYU Hospital for Joint Diseases, the first study of its kind in North American patients, and the first to document prevalence of both episodic and chronic daily headache in Behcet's.
PMID: 25091130
ISSN: 1534-3081
CID: 1105272
Who decides if research will be published: Authors or sponsors? [Letter]
Yazici, Yusuf
PMID: 24757091
ISSN: 2151-464x
CID: 898902
Two-Year Results from the AMPLE Trial: Low Disease Activity and Association Between Remission and Changes in Physical Function and Radiographic Outcomes with Subcutaneous Abatacept or Adalimumab [Meeting Abstract]
Fleischmann, Roy; Schiff, Michael; Weinblatt, Michael; Maldonado, Michael; Massarotti, Elena; Yazici, Yusuf
ISI:000338923700102
ISSN: 1499-2752
CID: 2734122
Behcet Syndrome Manifestations and Activity in the United States versus Turkey - A Cross-sectional Cohort Comparison
Sibley, Cailin; Yazici, Yusuf; Tascilar, Koray; Khan, Nafiz; Bata, Yasmin; Yazici, Hasan; Goldbach-Mansky, Raphaela; Hatemi, Gulen
OBJECTIVE: To compare clinical manifestations and activity of Behcet syndrome (BS) in the United States versus Turkey using validated outcome measures. METHODS: Consecutive patients with BS from the US National Institutes of Health (NIH), New York University, and the University of Istanbul were evaluated. Disease activity was measured using the Behcet's Syndrome Activity Scale (BSAS) and the Behcet's Disease Current Activity Form (BDCAF) with quality of life measured by the Behcet Disease Quality of Life (BDQOL) form. One-way ANOVA, t-tests, and multivariate regression analyses were performed. RESULTS: Mean age did not differ between sites; however, more women were seen in the United States versus in Turkey (p < 0.001), and disease duration was longer in the United States (p = 0.02). Organ manifestations were similar for oral and genital ulcers, skin disease, arthralgia, eye disease, and thrombosis. However, more gastrointestinal (p < 0.001) and neurologic disease (p = 0.003) was seen in the United States. BSAS and BDCAF scores were worse in the United States compared to Turkey (p = 0.013 and < 0.001, respectively). Worse mean BDQOL scores were observed at the NIH compared to Istanbul (not significant). Multivariable regression models showed worse scores in ethnically atypical patients for BSAS and BDCAF (p = 0.04 and p = 0.001), American patients for BDCAF (p = 0.01), older age for BDCAF (p = 0.005), and women for BDQOL (p = 0.01). CONCLUSION: Demographic and clinical manifestations of BS differ between sites with higher disease activity in the United States compared to Turkey. Referral patterns, age, sex, ethnicity, and country of origin may be important in these differences. These observations raise the question of whether pathogenic mechanisms differ in Turkish and American patients.
PMCID:4565792
PMID: 24931953
ISSN: 0315-162x
CID: 1036592
GENDER DIFFERENCES IN DISEASE ACTIVITY IN A PSORIATIC ARTHRITIS ROUTINE CARE COHORT [Meeting Abstract]
Reddy, SM; Scher, U; Swearingen, CJ; Yazici, Y
ISI:000346919804138
ISSN: 1468-2060
CID: 1599062
RANDOMIZATION TO PATIENT-REPORTED RAPID3 VERSUS PHYSICIAN-BASED CDAI TOOLS FOR PREDICTION OF TREATMENT RESPONSE AND ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB PEGOL: RESULTS FROM THE PREDICT STUDY [Meeting Abstract]
Curtis, JR; Churchill, M; Kivitz, A; Samad, A; Gauer, L; Coteur, G; Gervitz, L; Koetse, W; Melin, J; Yazici, Y
ISI:000346919802108
ISSN: 1468-2060
CID: 1598922